Loading…
Elite Health Center was selling unapproved and misbranded compounded semaglutide products online, claiming the compounds were "FDA approved" for diabetes treatment (2017) and obesity (2021), which falsely implied they were equivalent to FDA-approved drugs when compounded products are not FDA-approved. The company violated sections 502(a) and 502(bb) of the Federal Food, Drug, and Cosmetic Act by making false or misleading claims in their website advertising and promotion. The FDA determined that these misbranded drugs were unlawfully introduced into interstate commerce through the company's internet sales operations.